Clinical Oncology
Volume 20, Issue 5 , Pages 325-326 , June 2008

The HiLo Trial: a Multicentre Randomised Trial of High- versus Low-dose Radioiodine, with or without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation after Surgery for Differentiated Thyroid Cancer

  • U. Mallick

      Affiliations

    • Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle, UK
    • Corresponding Author InformationAuthor for correspondence: U. Mallick, Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK.
    • ,
  • C. Harmer

      Affiliations

    • The Royal Marsden Hospital, London, UK
    • ,
  • A. Hackshaw

      Affiliations

    • Cancer Research UK & UCL Cancer Trials Centre, London, UK

Received 5 March 2008 ,Accepted 10 March 2008.

References 

  1. Cancer Research UK . Cancer statistics 2005. Available from: http://info.cancerresearchuk.org/cancerstats/types/thyroid/incidence/[updated August 2007]
  2. American Cancer Society . Cancer facts and figures 2008. Available from: http://www.cancer.org/docroot/STT/stt_0.asp[accessed 04.03.08]
  3. British Thyroid Association . Guidelines for the management of thyroid cancer in adults. London: Royal College of Physicians; 2007;
  4. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638–1644
  5. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–142
  6. Hackshaw AK, Harmer C, Mallick U, Haq M, Franklyn J. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrin Metab. 2007;92(1):28–38
  7. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international randomized controlled study. J Clin Endocrinol Metab. 2006;91(3):926–932
  8. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542–3546

PII: S0936-6555(08)00151-9

doi: 10.1016/j.clon.2008.03.010

Clinical Oncology
Volume 20, Issue 5 , Pages 325-326 , June 2008

Article Tools